The Markesbery Symposium is held annually in memory of the late William R. Markesbery, MD, founding director of the Sanders-Brown Center on Aging and Alzheimer's Disease Research Center. Dr. Markesbery's legacy of groundbreaking research has formed the bedrock for our quest to understand and treat Alzheimer's disease and to improve the quality of life of older adults. The two-day symposium features a daylong scientific meeting with poster session followed by a half-day community session to which the public is invited free of charge. An “Ask the Experts” panel is a popular component of the community session.
2024 Markesbery Symposium
The 2024 Markesbery Symposium will be held September 27-28. Check back as more details will be coming soon!
Scientific Session Past Presenters | ||
---|---|---|
2023 | Malu Tansey, PhD | Targeting Chronic Inflammation and the Gut-Brain Axisto Reduce Risk for Neurodegeneration |
2023 | David Morgan, PhD | Immune Activation in Models of Tauopathy |
2023 | Anika Hartz, PhD | Blood-Brain Barrier Repair to Improve Cognition in Alzheimer’s Disease |
2023 | David Fardo, PhD | A Genome-wide Association Study of Neuropathological Endophenotypes |
2022 | Ann McKee, MD | CTE: What Is It? What Is Its Relationship to Repetitive Head Impacts? |
2022 | Josh Grill, PhD | Preclinical Alzheimer’s Disease: Translating Cutting Edge Research into Everyday Practice |
2022 | Kate Foley, PhD | The Role of Human Plasma Biomarkers in the Diagnosis of Dementia |
2022 | Mark Ebbert, PhD | Using Long-Read Sequencing Technologies to Identify Key Drivers and Biomarkers in Alzheimer’s Disease |
2022 | Ryan Shahidehpour, Graduate Student and TRIAD T32 Trainee, | The Role of Dystrophic Microglia in Neurodegenerative Diseases Related to Aging |
2022 | Christopher Norris, PhD | Strategies for Targeting Astrocyte Reactivity in Alzheimer’s Disease and Related Dementias (STAR-AD/ADRD) |
2021 | Frederick A. Schmitt, PhD | 35 Years of the University of Kentucky Alzheimer’s DiseaseCenter: Past Discoveries and Future Directions |
2021 | Maj-Linda Selenica, PhD | Investigating the role of hypusinated eIF5A in AD and relatedTDP-43 proteinopathy disorders |
2021 | Josh Morganti, PhD | Diversity and susceptibility of microglial responses in a mousemodel of mixed etiology dementia |
2020 | Ronald Petersen, MD, PhD | Is MCI Still a Viable Construct in 2020? |
2020 | Alison Goate, D.Phil. | Human Genetics Implicates Efferocytosis in Alzheimer’s Disease |
2019 | Adam Brickman, PhD | Reconsidering Harbingers of Alzheimer’s Disease: Risk Factors, Biomarkers, and White Matter Hyperintensities |
2019 | Olivier Thibault, PhD | Ups and Downs of Calcium in Models of Aging and AD |
2019 | Jenna Gollihue, PhD | Manipulating Astrocytes for Better Brain Health |
2019 | Kendra Hargis-Staggs, PhD | Gray and White Matter Neurovascular Ceruloplasmin Expression in Alzheimer’s Disease |
2019 | Daniel C. Lee, PhD | Emerging Role of the Polyamine Stress Response in Alzheimer’s Disease |
2018 | Monica W. Parker, MD | Engaging the underserved in brain health and research |
2018 | Sanjay Asthana, MD, FACP | Preclinical biomarkers of Alzheimer’s disease: emerging concepts & clinical utility |
2018 | Donna Wilcock, PhD | Identification of novel fluid biomarkers for vascular cognitive impairment and dementia (VCID) |
2018 | Lance Johnson, PhD | Metabolic reprogramming and Alzheimer’s disease risk: the role of ApoE4 |
2018 | Elizabeth Head, PhD | Changes in cerebrovascular pathology as a function of age and Alzheimer disease in Down syndrome |
2018 | Dr. Gregory Jicha, MD, PhD | Modulation of micro-RNA pathways by gemfibrozil in predementia Alzheimer disease: clinical translational research at Sanders-Brown Center on Aging |
Community Session Past Presenters | ||
---|---|---|
2023 | Malu Tansey, PhD | Why Gut Health Matters for Brain Health |
2023 | David Morgan, PhD | Immunotherapy for Alzheimer’s Disease: 25 Years from Mouse Models to Approved Treatment in People Living with Alzheimer’s |
2023 | Alaine Reschke-Hernandez, PhD, MT-BC | Harmonizing Music Therapy Research in Dementia Care |
2023 | Frederick Schmitt, PhD | Trisomy 21: Providing Insights into Dementia |
2023 | Gregory Jicha, MD, PhD | Anti-Amyloid Therapy: Who’s Benefitting and How Do We Move Forward? |
2022 | Josh Grill, PhD | Can We Prevent Alzheimer’s? |
2022 | Ann McKee, MD | The Inconvenient Truth About Football |
2022 | Lauren Whitehurst, PhD | “Sleep Tight”, “Memory Bright”: Research on the Cost of Racial Sleep Disparities for Memory Processing |
2022 | Elizabeth Rhodus, PhD | Creating Harmony While Caring for People Living with Dementia |
2021 | Allan Levey, MD, PhD | Accelerating Progress for Treatments for Alzheimer’s Disease? |
2021 | Gregory Jicha, MD, PhD, & Erin Abner, PhD | Aducanamab / Aduhelm: The controversial new treatment for Alzheimer’s disease |
2020 | Maria Carrillo, PhD | Advancing the Science: The Latest in Alzheimer’s and Dementia Research |
2020 | Daniel Moga, MD, PhD | My Medications and Why Should I Know about Them |
2020 | Peter Nelson, MD, PHD | LATE: What It Is, Why It’s Important, and How We Might Beat It |
2019 | Laura D. Baker, PhD | Can LIFESTYLE Impact Health of the Mind As We Age? |
2019 | Gregory Jicha, MD, PhD | Clinical Trials Update |
2018 | Sanjay Asthana, MD, FACP | Early Diagnosis and Prevention of Alzheimer’s Disease: Role of Biomarkers and Estrogen Hormone |
2018 | Monica W. Parker, MD | Alzheimer’s and The Brain: What We Know |
Markesbery Symposium Programs & Agendas From Years Past
To view past Markesbery Symposium presentations, visit the Markesbery Symposium YouTube playlist.